Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
ABSTRACT Introduction This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML. Methods Endpoints included complete remission rate (CRR), overall resp...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70051 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Introduction This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML. Methods Endpoints included complete remission rate (CRR), overall response rate (ORR), overall survival (OS) and safety. Results Eighteen and 36 patients were enrolled into the unfit and R/R AML arms, respectively. CRR was 38.9% and 25.0%, ORR was 66.7% and 38.9%, and median OS was 15.3 and 10.5 months in the unfit AML and R/R AML arms, respectively. No dose‐limiting toxicities or magrolimab‐related deaths occurred. Conclusion Magrolimab was safely combined with existing AML therapies with no new safety signals. Clinical Trial Registration This trial was registered at www.clinicaltrials.gov as NCT04778410. |
|---|---|
| ISSN: | 2688-6146 |